GLP-1 for Longevity with Dr. Fermin Barrueto
GLP-1 for Longevity with Dr. Fermin Barrueto  
Podcast: GLP-1 Hub: Support, Community, and Weight Loss
Published On: Mon Apr 28 2025
Description: In this episode of the GLP-1 Hub podcast, I speak with Dr. Fermin Barretto about the multifaceted benefits of GLP-1 medications beyond weight loss, including their impact on brain health, addiction pathways, and mental well-being. We discuss the transition from end-of-life care to preventative health, the importance of personalized treatment plans, and the management of side effects associated with GLP-1s. The conversation also touches on the future of GLP-1s and other peptides in the realm of longevity and cognitive improvement.Check out this episode's sponsor: Relesium.com and use the code GLP1Hub10 for 10% off your first orderAbout Dr. Barrueto:Co-Founder and Medical Director of LongJuve Medspa. Emergency Physician and Medical Toxicologist who has spent years treating patients at the end of the disease continuum. He has taken that knowledge and refocused on prevention, longevity, and rejuvenation. Learn more at: www.longjuve.comFollow Dr. Barrueto on Instagram: @dr.ferminbarruetoWant to Learn More about GLP-1 Hub?Join the Steady State newsletter and get a FREE 7-day meal plan + weekly support and strategy to optimize your journey: http://join.glp-1hub.comJoin the membership:https://glp-1hub.com/membershipVisit our GLP-1 Hub store:https://shop.glp-1hub.comWant to connect more with GLP-1 Hub? Instagram:   https://www.instagram.com/glp1hubTiktok: https://www.tiktok.com/@glp1hubYouTube: https://www.youtube.com/@glp-1hub*Some of the links shared are affiliate links. When you make a purchase, I will receive a small commission at no cost to you. Thank you for supporting the show.*The content of this show is for informational purposes only and does not constitute medical advice. The goal of this show is to provide various points of view about GLP-1 Medications. The personal and professional opinion of the guests and their content does not necessarily reflect the opinion of Ana Reisdorf or GLP-1 Hub.